AU2020379171B2 - Methods of using IL-33 antagonists - Google Patents

Methods of using IL-33 antagonists Download PDF

Info

Publication number
AU2020379171B2
AU2020379171B2 AU2020379171A AU2020379171A AU2020379171B2 AU 2020379171 B2 AU2020379171 B2 AU 2020379171B2 AU 2020379171 A AU2020379171 A AU 2020379171A AU 2020379171 A AU2020379171 A AU 2020379171A AU 2020379171 B2 AU2020379171 B2 AU 2020379171B2
Authority
AU
Australia
Prior art keywords
antagonist
egfr
suitably
treatment
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020379171A
Other languages
English (en)
Other versions
AU2020379171A1 (en
Inventor
Maria BELVISI
Emma Suzanne Cohen
Rania DAGHER
Mahboobe GHAEDI
Kirsty HOUSLAY
Xavier ROMERO ROS
Sam STRICKSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2020379171A1 publication Critical patent/AU2020379171A1/en
Application granted granted Critical
Publication of AU2020379171B2 publication Critical patent/AU2020379171B2/en
Priority to AU2025213676A priority Critical patent/AU2025213676A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020379171A 2019-11-04 2020-11-03 Methods of using IL-33 antagonists Active AU2020379171B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025213676A AU2025213676A1 (en) 2019-11-04 2025-08-08 Methods of using il-33 antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206984.7 2019-11-04
EP19206984 2019-11-04
PCT/EP2020/080841 WO2021089563A1 (en) 2019-11-04 2020-11-03 Methods of using il-33 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025213676A Division AU2025213676A1 (en) 2019-11-04 2025-08-08 Methods of using il-33 antagonists

Publications (2)

Publication Number Publication Date
AU2020379171A1 AU2020379171A1 (en) 2022-06-09
AU2020379171B2 true AU2020379171B2 (en) 2025-05-08

Family

ID=68426347

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020379171A Active AU2020379171B2 (en) 2019-11-04 2020-11-03 Methods of using IL-33 antagonists
AU2025213676A Pending AU2025213676A1 (en) 2019-11-04 2025-08-08 Methods of using il-33 antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025213676A Pending AU2025213676A1 (en) 2019-11-04 2025-08-08 Methods of using il-33 antagonists

Country Status (10)

Country Link
US (1) US20220380450A1 (cg-RX-API-DMAC10.html)
EP (1) EP4054711A1 (cg-RX-API-DMAC10.html)
JP (2) JP7843701B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220093334A (cg-RX-API-DMAC10.html)
CN (2) CN122140920A (cg-RX-API-DMAC10.html)
AU (2) AU2020379171B2 (cg-RX-API-DMAC10.html)
CA (1) CA3158323A1 (cg-RX-API-DMAC10.html)
IL (1) IL292443A (cg-RX-API-DMAC10.html)
TW (1) TW202134261A (cg-RX-API-DMAC10.html)
WO (1) WO2021089563A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991847T3 (es) 2021-08-27 2024-12-05 Medimmune Ltd Tratamiento de enfermedad pulmonar obstructiva crónica con un anticuerpo anti-interleucina-33
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016156440A1 (en) * 2015-03-31 2016-10-06 Medimmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
WO2015032932A1 (en) * 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド 抗インターロイキン−３３抗体及びその使用
SG11201808693WA (en) 2016-04-27 2018-11-29 Pfizer Anti-il-33 antibodies, compositions, methods and uses thereof
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
WO2018204598A1 (en) 2017-05-03 2018-11-08 The University Of North Carolina At Chapel Hill Methods for diagnosing or predicting chronic bronchitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016156440A1 (en) * 2015-03-31 2016-10-06 Medimmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALLINNE JEANNE ET AL, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 144, no. 6, 25 September 2019 (2019-09-25), pages 1624, XP085935196, ISSN: 0091-6749, [retrieved on 20190925], DOI: 10.1016/J.JACI.2019.08.039 *

Also Published As

Publication number Publication date
US20220380450A1 (en) 2022-12-01
EP4054711A1 (en) 2022-09-14
AU2020379171A1 (en) 2022-06-09
IL292443A (en) 2022-06-01
JP2026012782A (ja) 2026-01-27
JP2023500492A (ja) 2023-01-06
JP7843701B2 (ja) 2026-04-10
AU2025213676A1 (en) 2025-08-28
KR20220093334A (ko) 2022-07-05
CA3158323A1 (en) 2021-05-14
CN122140920A (zh) 2026-06-05
WO2021089563A1 (en) 2021-05-14
CN114901361A (zh) 2022-08-12
TW202134261A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
JP2026012782A (ja) Ｉｌ－３３アンタゴニストの使用方法
US20250042986A1 (en) Stem cell factor inhibitor
US20220162322A1 (en) Anti bdca-2 antibodies
US20250074978A1 (en) Antibodies for il-17c
WO2016002820A1 (ja) 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
EA052516B1 (ru) Способы применения антагонистов il-33
US20220363748A1 (en) Anti il-33 therapeutic agent for treating renal disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)